Harrow, Inc. Amortization of Debt Issuance Costs and Discounts
Harrow, Inc. (HROW) reported Amortization of Debt Issuance Costs and Discounts of $851.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-10
- Harrow, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was $400.00K, a 68.97% decline year-over-year.
- Harrow, Inc. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $451.00K, a 64.63% decline year-over-year.
- Harrow, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was $358.00K, a 70.66% decline year-over-year.
- Harrow, Inc. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was $1.13M, a 9.09% increase year-over-year.
- Harrow, Inc. amortization of debt issuance costs and discounts for fiscal 2025 was $4.05M, a 3.69% decline from fiscal 2024.
- Harrow, Inc. amortization of debt issuance costs and discounts for fiscal 2024 was $4.21M, a 2.64% increase from fiscal 2023.
- Harrow, Inc. amortization of debt issuance costs and discounts for fiscal 2023 was $4.10M, a 423.91% increase from fiscal 2022.
- Harrow, Inc. amortization of debt issuance costs and discounts for fiscal 2022 was $782.00K, a 15.51% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $851.00K 10-Q · filed 2026-08-10 | $1.21M derived: sum of 3 quarters · filed 2026-08-10 | $2.34M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $451.00K 10-Q · filed 2026-05-11 | $809.00K derived: sum of 2 quarters · filed 2026-05-11 | $1.94M derived: sum of 3 quarters · filed 2026-05-11 | $3.23M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $358.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.49M derived: sum of 2 quarters · filed 2026-03-02 | $2.77M derived: sum of 3 quarters · filed 2026-08-10 | $4.05M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.42M derived: sum of 2 quarters · filed 2026-08-10 | $3.69M 10-Q · filed 2025-11-10 | $4.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.56M 10-Q · filed 2026-08-10 | $3.78M derived: sum of 3 quarters · filed 2026-08-10 | $4.82M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.27M 10-Q · filed 2026-05-11 | $2.50M derived: sum of 2 quarters · filed 2026-05-11 | $3.53M derived: sum of 3 quarters · filed 2026-05-11 | $4.50M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.25M derived: sum of 2 quarters · filed 2026-03-02 | $3.23M derived: sum of 3 quarters · filed 2026-03-02 | $4.21M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.01M derived: sum of 2 quarters · filed 2025-11-10 | $2.98M 10-Q · filed 2025-11-10 | $4.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $975.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.95M 10-Q · filed 2025-08-11 | $3.48M derived: sum of 3 quarters · filed 2026-03-02 | $4.42M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $976.00K 10-Q · filed 2025-05-08 | $2.50M derived: sum of 2 quarters · filed 2026-03-02 | $3.45M derived: sum of 3 quarters · filed 2026-03-02 | $4.31M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.47M derived: sum of 2 quarters · filed 2026-03-02 | $3.34M derived: sum of 3 quarters · filed 2026-03-02 | $4.10M 10-K · filed 2026-03-02 |
| 2023-09-30 | $945.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $1.81M derived: sum of 2 quarters · filed 2024-11-14 | $2.57M 10-Q · filed 2024-11-14 | $2.77M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $862.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.62M 10-Q · filed 2024-08-07 | $1.82M derived: sum of 3 quarters · filed 2024-08-07 | $2.02M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $761.00K 10-Q · filed 2024-05-13 | $958.00K derived: sum of 2 quarters · filed 2024-05-13 | $1.16M derived: sum of 3 quarters · filed 2024-05-13 | $1.35M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $394.00K derived: sum of 2 quarters · filed 2024-03-19 | $589.00K derived: sum of 3 quarters · filed 2024-03-19 | $782.00K 10-K · filed 2024-03-19 |
| 2022-09-30 | $197.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $392.00K derived: sum of 2 quarters · filed 2023-11-13 | $585.00K 10-Q · filed 2023-11-13 | $782.00K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $195.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $388.00K 10-Q · filed 2023-08-09 | $585.00K derived: sum of 3 quarters · filed 2023-08-09 | $777.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $193.00K 10-Q · filed 2023-05-11 | $390.00K derived: sum of 2 quarters · filed 2023-05-11 | $582.00K derived: sum of 3 quarters · filed 2023-05-11 | $774.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $197.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $389.00K derived: sum of 2 quarters · filed 2023-03-23 | $581.00K derived: sum of 3 quarters · filed 2023-03-23 | $677.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $192.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $384.00K derived: sum of 2 quarters · filed 2022-11-14 | $480.00K 10-Q · filed 2022-11-14 | $583.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $192.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $288.00K 10-Q · filed 2022-08-09 | $391.00K derived: sum of 3 quarters · filed 2022-08-09 | $502.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $96.00K 10-Q · filed 2022-05-05 | $199.00K derived: sum of 2 quarters · filed 2022-05-05 | $310.00K derived: sum of 3 quarters · filed 2022-05-05 | $393.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $103.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $214.00K derived: sum of 2 quarters · filed 2022-03-10 | $297.00K derived: sum of 3 quarters · filed 2022-03-10 | $457.00K 10-K · filed 2022-03-10 |
| 2020-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $194.00K derived: sum of 2 quarters · filed 2021-11-09 | $354.00K 10-Q · filed 2021-11-09 | $472.00K derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $83.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $243.00K 10-Q · filed 2021-08-10 | $361.00K derived: sum of 3 quarters · filed 2021-08-10 | $492.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $160.00K 10-Q · filed 2021-05-11 | $278.00K derived: sum of 2 quarters · filed 2021-05-11 | $409.00K derived: sum of 3 quarters · filed 2021-05-11 | $537.00K derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $118.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-08 | $249.00K derived: sum of 2 quarters · filed 2021-03-08 | $377.00K derived: sum of 3 quarters · filed 2021-03-08 | $512.00K 10-K · filed 2021-03-08 |
| 2019-09-30 | $131.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $259.00K derived: sum of 2 quarters · filed 2020-11-09 | $394.00K 10-Q · filed 2020-11-09 | $541.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $128.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $263.00K 10-Q · filed 2020-08-10 | $410.00K derived: sum of 3 quarters · filed 2020-08-10 | $562.00K derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $135.00K 10-Q · filed 2020-05-11 | $282.00K derived: sum of 2 quarters · filed 2020-05-11 | $434.00K derived: sum of 3 quarters · filed 2020-05-11 | $589.00K derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-13 | $299.00K derived: sum of 2 quarters · filed 2020-03-13 | $454.00K derived: sum of 3 quarters · filed 2020-03-13 | $613.00K 10-K · filed 2020-03-13 |
| 2018-09-30 | $152.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $307.00K derived: sum of 2 quarters · filed 2019-11-13 | $466.00K 10-Q · filed 2019-11-13 | $632.00K derived: sum of 4 quarters · filed 2019-11-13 |
| 2018-06-30 | $155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $314.00K 10-Q · filed 2019-08-14 | $480.00K derived: sum of 3 quarters · filed 2019-08-14 | $660.00K derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $159.00K 10-Q · filed 2019-05-09 | $325.00K derived: sum of 2 quarters · filed 2019-05-09 | $505.00K derived: sum of 3 quarters · filed 2019-05-09 | $801.00K derived: sum of 4 quarters · filed 2019-05-09 |
| 2017-12-31 | $166.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $346.00K derived: sum of 2 quarters · filed 2019-03-12 | $642.00K derived: sum of 3 quarters · filed 2019-03-12 | $978.00K 10-K · filed 2019-03-12 |
| 2017-09-30 | $180.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $476.00K derived: sum of 2 quarters · filed 2018-11-13 | $812.00K 10-Q · filed 2018-11-13 | |
| 2017-06-30 | $296.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-06 | $632.00K 10-Q · filed 2018-08-06 | ||
| 2017-03-31 | $336.00K 10-Q · filed 2018-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |